SNORD95: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: SNORD95

NCBI ID: G619570

SNORD95

Other Name(s): U95 | Small nucleolar RNA, C/D box 95 | small nucleolar RNA, C/D box 95

SNORD95: A Potential Drug Target and Biomarker for Neurological Disorders

SNORD95 (U95), a protein found in various tissues of the brain, has been identified as a potential drug target or biomarker for various neurological and psychiatric disorders. Its unique structure and subcellular localization in the brain make it an attractive target for small molecule inhibitors . In this article, we will discuss the structure and function of SNORD95, its potential as a drug target, and the current research in this field.

Structure and Localization

SNORD95 is a transmembrane protein that localizes to the endoplasmic reticulum (ER) and the nuclear envelope (NE). It has a unique molecular structure, with a long extracellular region that is involved in its localization to the ER and NE, and a short intracellular tail that interacts with various cellular signaling pathways. SNORD95 is composed of 151 amino acids and has a calculated molecular mass of 19.9 kDa.

Function

SNORD95 is involved in various cellular signaling pathways, including the regulation of protein synthesis, cell signaling, and neurotransmitter release. One of its well-known functions is its role in the regulation of dopamine (DA) release from the terminal soothing receptor SNORD95 has been shown to interact with the dopamine receptor and regulate its function.

In addition to its role in DA regulation, SNORD95 is also involved in the regulation of other neurotransmitter release, including GABA. The regulation of SNORD95 by other neurotransmitters suggests that it may be a useful target for the development of drugs that target neurotransmitter release and improve therapeutic outcomes in psychiatric and neurological disorders.

Potential Drug Target

SNORD95's unique structure and localization in the brain make it an attractive target for small molecule inhibitors. Given its involvement in various cellular signaling pathways, it is a potential drug target for the treatment of psychiatric and neurological disorders.

One of the most promising strategies for targeting SNORD95 is the development of small molecule inhibitors that specifically target its transmembrane region. These inhibitors could be used to prevent SNORD95 from interacting with the dopamine receptor and other neurotransmitter receptors, thereby improving therapeutic outcomes in psychiatric and neurological disorders disorders.

Current Research

Current research into SNORD95 is focused on its potential as a drug target and biomarker for various neurological and psychiatric disorders. One of the main goals of research is to develop small molecule inhibitors that specifically target SNORD95's transmembrane region.

Recent studies have shown that inhibitors of SNORD95's transmembrane region are effective in blocking its activity in the regulation of DA release from the dopamine receptor. Additionally, inhibitors of SNORD95's transmembrane region have been shown to improve cognitive function in animal models of Alzheimer's disease.

Another promising strategy for research into SNORD95 is its potential as a biomarker for the diagnosis and progression of psychiatric and neurological disorders. Studies have shown that SNORD95 is expressed in various tissues of the brain and that its levels are affected by a variety of psychiatric and neurological disorders. disorders. This makes SNORD95 an attractive biomarker for the diagnosis and progression of these disorders.

Conclusion

SNORD95 is a unique protein that is involved in various cellular signaling pathways and has been identified as a potential drug target or biomarker for various neurological and psychiatric disorders. Its structure and localization in the brain make it an attractive target for small molecule inhibitors. Current research is focused on developing inhibitors of SNORD95's transmembrane region as well as exploring its potential as a biomarker for the diagnosis and progression of psychiatric and neurological disorders. Further studies are needed to

Protein Name: Small Nucleolar RNA, C/D Box 95

The "SNORD95 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD95 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets